Therapeutics Company Publishes EEG Findings From Alzheimer's Treatment Study
$CGTX - Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer's Disease.
Disclaimer: The following article provides an overview of recent findings from a study conducted by Cognition Therapeutics, Inc. regarding the use of CT1812 in treating mild-to-moderate Alzheimer's disease. This article is intended for informational purposes only and should not be considered medical advice. Always consult with a …